Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 406

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 406
---
 (%) [95% CI]      |     | 33.3 [0.8 – 90.6]      |     | 8.0 [1.0 – 26.0]        |     | 12.0 [2.5 – 31.2]     |
| DCRR (%) [95% CI]     |     | 33.3 [0.8 – 90.6]      |     | 20.0 [6.8 – 40.7]       |     | 16.0 [4.5 – 36.1]     |

Note: A hyphen (-) indicates no events were reported. n = number of patients with an event; N = number of patients; NR = non -resectable . Percentages are based on the number of patients. CR = complete response; PR = partial remission; SD = stable disease; PD = progressive disease; ORR = objective response rate (CR and PR); DCR = disease control rate (CR, PR, and SD). The clinical response was assessed by recurrence -freesurvival after re -operation(RFS) (in the 10 7CFU/mL resectable group), time -to-progression(TTP), progression free survival (PFS), and overall survival (OS). In the patients who underwent tumor resection (10 7CFU/mL resectable group), disease progression occurred only in Patient 01 -17with an RFS of 1.8. Patient 01 -14was censored with an RFS of 20.9 months. The results for TTP and PFS were identical, with an overall median of 2.7 months and range of 1.2 to 13.8 months in the non -resectedpatients (Total NR group). The median OS in the Total NR group was 11.1 months (95% CI: 8.5 – 15.1) with a range of 3.8 to 38.2 months. At the time of database lock, 1 patient in the 10 7CFU/mL resectable group was alive and had stable disease without post -resectionrecurrence, while 3 patients in the 10 7CFU/mL non -resectablegroup were alive with progressive disease in longterm follow -up. VXM01 phase I/II clinical trial — Immune response The effect of VXM01 plus